New blood test improves detection and staging of tuberculosis

Tuberculosis remains a global health challenge: the abstract opens by noting that approximately 25% of the world’s population has been infected with Mycobacterium tuberculosis (Mtb). Current tools for detecting Mtb exposure and disease include Interferon-gamma (IFNγ) release assays (IGRA), but these tests have known limitations, particularly in telling apart people who are infected from those who have active disease. To address this gap, a team led by corresponding author Christopher Sundling evaluated a different approach: a multiplex FluoroSpot assay that measures three cytokines at once — IFNγ, TNF, and IL2 — produced by immune cells when they see Mtb. The researchers exposed peripheral blood mononuclear cells from three groups to Mtb antigens ESAT-6, CFP-10, and EspC. The groups were people with TB disease (n=24), people with TB infection (n=63), and IGRA-negative controls (n=27). By testing many cells for multiple signals simultaneously, the study aimed to detect finer patterns of immune response that single-readout tests might miss, and to learn whether different combinations of cytokines map to different stages along the TB infection-to-disease spectrum.

The core method was a multiplex FluoroSpot assay that records individual cells secreting IFNγ, TNF, and IL2 in response to the Mtb antigens ESAT-6, CFP-10, and EspC. Peripheral blood mononuclear cells from study participants were stimulated with these antigens and the assay counted cells that secreted any of the three cytokines alone or in combination. The key finding reported in the abstract is that cells secreting all three cytokines (IFNγ/IL2/TNF triple-secreting cells) detected Mtb-specific immune responses with higher sensitivity and specificity than commercially available IGRA methods. In addition to this improved overall detection, the FluoroSpot profiles revealed distinct cytokine patterns associated with different stages of TB infection and disease. The study therefore preserved the exact names of the cytokines and antigens tested (IFNγ, TNF, IL2, ESAT-6, CFP-10, EspC) and compared the multiplex readout directly against existing IGRA tests, using the defined sample groups of TB disease (n=24), TB infection (n=63), and IGRA-negative controls (n=27).

If the findings hold up in further work, a multiplex FluoroSpot that measures IFNγ, TNF, and IL2 could offer two practical benefits. First, it may improve diagnosis by catching more true cases and reducing false positives compared with single-analyte IGRA tests, thanks to the higher sensitivity and specificity reported for IFNγ/IL2/TNF triple-secreting cells. Second, the distinct cytokine signatures linked to recent or remote infection and to active disease could help clinicians and public health teams distinguish who is merely infected and who has progressed toward disease — information that affects decisions about treatment, monitoring, and control measures. The authors are cautious, however: the abstract stresses that these results now need validation in larger and more diverse cohorts, including people with immunosuppressive conditions, before the assay could be recommended for routine clinical or public health use. Such validation would confirm whether the improved detection and differentiation are robust across populations and settings.